Diffuse Large B Cell Lymphoma  >>  Monjuvi (tafasitamab-cxix)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

22 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Monjuvi (tafasitamab-cxix) / Incyte
NCT01685008 / 2012-002659-41: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Checkmark In relapsed/refractory NHL at ASH 2016
Dec 2016 - Dec 2016: In relapsed/refractory NHL at ASH 2016
Checkmark Single-agent MOR208 in r/r NHL at ASCO 2016
Jun 2016 - Jun 2016: Single-agent MOR208 in r/r NHL at ASCO 2016
Checkmark B-cell NHL at ASH 2015
More
Completed
2a
92
Europe, US
MOR00208 (formerly Xmab 5574), MOR208
MorphoSys AG
Non-Hodgkin Lymphoma
04/22
04/22
2020-004977-38: Study to determine the efficacy of Tafasitamab and lenalidomide administered in association with rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older .

Not yet recruiting
2
71
Europe
Tafasitamab, MOR208, Powder and solvent for solution for injection, Capsule, hard, Zelvina
LYSARC, Incyte
Frontline DLBCL, Diffuse Large B Cells Lymphoma, Diseases [C] - Cancer [C04]
 
 
2021-003658-22: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Estudio en fase II de plamotamab en combinación con tafasitamab más lenalidomida en comparación con tafasitamab más lenalidomida en linfoma difuso de células B grandes recidivante o resistente al tratamiento

Not yet recruiting
2
240
Europe
Plamotamab, Lenalidomide, MONJUVI, XmAb13676, Lenalidomide, Concentrate for solution for infusion, Capsule, hard, Powder for solution for infusion, MONJUVI
Xencor, Inc., Xencor, Inc.
Relapsed or refractory diffuse large B-cell lymphoma Linfoma difuso de células B grandes recidivante o resistente al tratamiento, A type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. Un tipo de linfoma no Hodgkin (LNH). El LNH es un cáncer del sistema linfático., Diseases [C] - Cancer [C04]
 
 
L-MIND, NCT02399085 / 2014-004688-19: Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Hourglass Jun 2023 - Jun 2023 : Presentation of data from L-MIND trial for R/R DLBCL at EHA 2023
Hourglass Mar 2022 - Dec 2022 : Initiation of a study in combination with plamotamab and lenalidomide in r/r DLBCL, 1L DLBCL and r/r follicular lymphoma
Checkmark Approved in Hong Kong in combination with lenalidomide for r/r DLBCL
Dec 2022 - Dec 2022: Approved in Hong Kong in combination with lenalidomide for r/r DLBCL
Checkmark Submitted MAA in Brazil in combination with lenalidomide for R/R DLBCL who are not eligible for ASCT
More
Completed
2
81
Europe, US, RoW
Tafasitamab, MOR00208, Lenalidomide, LEN, Revlimid®
MorphoSys AG
Diffuse Large B-cell Lymphoma
11/22
04/23
NCT05328102: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Terminated
2
3
Europe, US
Plamotamab, XmAb13676, Tafasitamab, Lenalidomide
Xencor, Inc.
Diffuse Large-cell B-cell Lymphoma
02/23
02/23
VERLen, NCT04974216: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Active, not recruiting
2
71
Europe
Tafasitamab, MOR208, Lenalidomide, Rituximab
The Lymphoma Academic Research Organisation
DLBCL
07/24
12/26
NCT05821088: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recruiting
2
37
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
David Bond, MD
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
12/24
12/25
SMART STOP, NCT04978584: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, Leurocristine, VCR, Vincrystine
M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
01/25
01/25
ICP-CL-00901, NCT05552937: Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
2
50
RoW
Tafasitamab and Lenalidomide
Beijing InnoCare Pharma Tech Co., Ltd.
DLBCL
04/25
04/27
NCT05615636: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting
2
36
US
Mosunetuzumab, RO7030816, Polatuzumab vedotin, Tafasitamab, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
08/25
08/27
NCT05890352: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recruiting
2
227
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Tazemetostat, E7438, EPZ-6438, EPZ6438, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
SWOG Cancer Research Network, National Cancer Institute (NCI), BeiGene, Ipsen, Incyte Corporation
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
12/26
01/29
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Calendar Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
NCT04882163: Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Withdrawn
1b/2
0
Europe, US, RoW
CC-220, Iberdomide, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide
Celgene
Lymphoma, B-Cell
04/26
04/29
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
NCT05351593: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Recruiting
1/2
35
US
Tafasitamab, MOR208, Lenalidomide, Revlimid
James Rubenstein, Incyte Corporation
CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
09/25
06/26
topMIND, NCT04809467 / 2020-005591-35: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Hourglass Jan 2023 - Dec 2023 : Proof-of-concept data from TopMIND trial in combination with parsaclisib for r/r NHL or CLL
Active, not recruiting
1/2
54
Europe, US
tafasitamab, INCMOR00208, parsaclisib, INCB050465
Incyte Corporation
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
12/24
12/24
MINDway, NCT05222555 / 2021-003855-40: Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Active, not recruiting
1/2
53
Europe, US, RoW
Tafasitamab, INCMOR00208, MOR00208, Xmab5574, Lenalidomide
Incyte Corporation
Diffuse Large B Cell Lymphoma
11/24
10/27
J-MIND, NCT04661007: To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Recruiting
1/2
65
Japan
tafasitamab, INCMOR00208, MOR00208, Xmab5574, lenalidomide, parsaclisib, R-CHOP
Incyte Biosciences Japan GK
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
05/25
07/26
NCT04607772: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Suspended
1/2
350
US
Selinexor, KPT-330, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Karyopharm Therapeutics Inc
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
12/25
12/25
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/26
07/26
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
NCT05626322: Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
1/2
4
Japan, US, RoW
Maplirpacept, PF-07901801, TTI-622, Tafasitamab, Minjuvi, Monjuvi, Lenalidomide, Revlimid
Pfizer, MorphoSys AG, Incyte Corporation
Diffuse Large B-Cell Lymphoma
08/24
05/25

Download Options